Status: Not yet recruiting
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
To learn about the safety and effects of revumenib in combination with blinatumomab in patients with newly diagnosed or relapsed/refractory Ph-negative ALL with a KMT2A rearrangement.
Participants needed: 20
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jun 23, 2026Locations: 1
Eligibility criteria
Participants > 18 years of age with relapsed and/or refractory (defined as >5% b... [+25]
Active serious infection not controlled by oral or IV antibiotics [+9]